Sedivention, a Germany-based medtech startup, has raised €2.9 million in a seed funding round led by bmp Ventures alongside the IBG funds. Additional investors include the strategic investment arm of a global medtech company, High-Tech Gründerfonds (HTGF), superangels, and Cambridge Ventures.
The company is developing a minimally invasive, one-time outpatient therapy for the treatment of obesity, a condition expected to affect more than one billion people globally in the coming years. Existing treatment options, including bariatric surgery and drug therapies, remain limited due to their invasiveness, cost, or long-term dependency.
Sedivention’s approach is based on a targeted cryo procedure delivered via a specially designed balloon catheter, similar to a gastroscopy. The therapy uses precise cryoablation to interrupt hunger-related signals in the vagus nerve, aiming to address the underlying physiological mechanisms of obesity and enable sustained appetite reduction without surgery, implants, or ongoing medication.
Dr Ute Nollert, founder and Chief Medical Officer of Sedivention, said that obesity is a chronic disease requiring treatments that are both clinically effective and minimally invasive:
Our approach targets the underlying disruption in hunger and satiety regulation, enabling a lasting reduction in hunger without invasive procedures or lifelong treatment.
A functional prototype has already been developed and tested. With the new funding, Sedivention plans to advance product development, generate initial clinical data through a first-in-human study, and prepare for subsequent regulatory and market entry steps.
In the long term, Sedivention aims to replace highly invasive surgical procedures with outpatient interventional treatments, improving access to effective care.
Would you like to write the first comment?
Login to post comments